Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis

Trial Profile

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNM Au8 (Primary)
  • Indications Demyelinating disorders; Multiple sclerosis; Optic neuritis
  • Focus Therapeutic Use
  • Acronyms VISIONARY-MS
  • Most Recent Events

    • 14 Oct 2019 According to the Clene Nanomedicine media release, the National Multiple Sclerosis Society (NMSS) has awarded the company a research grant totaling more than $339,000. The Fast Forward grant will support pharmacodynamic studies to determine the effects of CNM-Au8 on various biological markers from patients in the VISIONARY-MS remyelination Phase 2 study.
    • 16 Jan 2019 Planned End Date changed from 31 Dec 2019 to 30 Mar 2020.
    • 16 Jan 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top